#HCT
🗣️ Present your work at one of the most influential global congresses in HCT, cellular therapy and gene therapy in Rotterdam. #EBMT27

Give your research the chance to gain global recognition and explore available awards, grants, abstract topics, and more ➡️ ebmt.org/annual-meeti...

#HCT #CellTherapy
September 29, 2026 at 1:18 PM
EN IMAGES. Retour en photographies sur un voyage apostolique historique
➡️ https://l.la-croix.com/HCT
September 28, 2026 at 6:30 PM
Earlier stem cell transplants may improve survival for youth with Shwachman-Diamond syndrome when high-risk features emerge, according to a study led by an expert at Cincinnati Children's and published in @nejm.org.
Earlier HCT Improves Survival for Youth with Shwachman-Diamond Syndrome - Research Horizons
Earlier stem cell transplants may improve survival for youth with Shwachman-Diamond syndrome when high-risk features emerge, according to a study led by an expert at Cincinnati Children's and publishe...
scienceblog.cincinnatichildrens.org
September 28, 2026 at 4:25 PM
🔬 New publication in Frontiers in Microbiology on MaaT013’s biological activity in aGvHD.
The study provides exploratory insights into gut barrier integrity, Treg responses, microbial engraftment and immune homeostasis.

👉 Full article: www.frontiersin.org/journals/mic...

@frontiersin.bsky.social
Frontiers | MaaT013 fecal microbiotherapy modulates key gastro-intestinal and immunological processes involved in GvHD pathogenesis in vitro and in vivo
BackgroundAcute graft-vs.-host disease (aGvHD) is a life-threatening complication of allogeneic hematopoietic cell transplantation (allo-HCT), where allogene...
www.frontiersin.org
September 28, 2026 at 3:34 PM
Authors used HCT 116 from @cellosaurus.bsky.social in their study. Including #RRIDs will make this less ambiguous.

SciScore made a table with this resource, see “Automated Services” module (download as csv, xml or #jats) #STMpublishing #OpenScience
www.biorxiv.org
September 27, 2026 at 12:00 PM
The future of HCT, cellular therapy, and gene therapy starts at #Tandem27.

Join experts, researchers, and clinicians as they share the latest advances shaping patient care.

📍 Orlando, FL | 📅 Feb. 17-20, 2027

Register: www.tandemmeetings.com/Registration...
September 25, 2026 at 10:00 PM
very useful! as is @meodai.bsky.social's meodai.github.io/cusphanger/
gonna be unstoppable this next map challenge
September 25, 2026 at 4:23 PM
Abstract submission for #Tandem27 is now open! ASTCT and CIBMTR invite you to share your research with your HCT, cell, and gene therapy colleagues in Orlando, FL, February 17-20, 2027! Learn more: www.tandemmeetings.com/Abstracts/Ab...
@astct.bsky.social
September 25, 2026 at 4:00 PM
💊 On #WorldPharmacistsDay, we recognise the the vital contributions of pharmacists in HCT and cellular therapy.

Discover how the EBMT Pharmacist Committee empowers the next generation of pharmacists: https://www.ebmt.org/ebmt/news/ebmt-celebrates-world-pharmacists-day-0
September 25, 2026 at 8:00 AM
"Another study reported stable cognitive functions in 9/11 (82%) survivors of HCT for ACALD" and sorry but HOW MANY HAVE DIED from HCT? pmc.ncbi.nlm.nih.gov/articles/PMC...
Neurocognitive and mental health impact of adrenoleukodystrophy across the lifespan: Insights for the era of newborn screening
X-linked adrenoleukodystrophy (ALD) is a rare inherited neurological disorder that poses considerable challenges for clinical management throughout the lifespan. Although males are generally more seve...
pmc.ncbi.nlm.nih.gov
September 25, 2026 at 5:18 AM
Idées neuves, corps-esprit alignés et rivalités pro pour les Verseau ce 25 septembre 2026 : quels signes guident votre amour, votre santé et vos finances ?
➡️ https://l.paroledemamans.com/Hct
September 25, 2026 at 4:34 AM
CAEBV in 21 patients: 62% had HCT; 3-yr survival 88%. CD4+ T-cell CAEBV had lower survival, needing prompt HCT to avoid lymphoma/leukemia. NK & T-cell cases showed long-term control. 🦠💉
Long-term Outcomes of Chronic Active Epstein–Barr Virus Infection in Childhood After Dominantly Infected Lymphocyte Subpopulation Management
Chronic active Epstein–Barr virus (EBV) disease (CAEBV) is an uncommon lethal infection involving EBV-infected T cells and/or natural killer (NK) cells, often complicated by hemophagocytic lymphohistiocytosis (HLH). Patients need curative hematopoietic cell transplantation (HCT), but the indication and timing remain unclear. This study aimed to assess the prognostic value of EBV-infected lymphocyte subsets.MethodsWe analyzed 52 pediatric/young-adult patients diagnosed with persistently EBV infection from 2003 to 2025 at a single tertiary center in Japan, excluding acute infectious mononucleosis and secondary immunodeficiencies. Dominant EBV-infected cell types (CD4+, CD8+, and γδ T cells; CD19+ B cells; and CD56+ NK cells) were determined at diagnosis of CAEBV (n = 21), EBV-HLH (n = 19), or inborn errors of immunity (IEI, n = 12). The long-term outcomes were analyzed by major infected cell types and treatment.ResultsCAEBV included 12 T-cell–dominant (6 CD4+, 4 CD8+, and 2 γδ) and 9 NK-cell–dominant infections. EBV-HLH and IEI exclusively involved CD8+ T-cell and B-cell infections, respectively. Thirteen CAEBV patients (62%) underwent HCT to control progression, including 5 patients who presented with HLH. The 3-year overall survival was 88%, although CD4+ T-cell disease (all CAEBV) showed a significantly lower survival rate. Posttransplant deaths occurred in 3 of 13 CAEBV patients and none of the EBV-HLH patients. Among 9 CAEBV patients with median 11-year progression-free survival without HCT, each one of CD4+ T-cell or NK-cell cases transformed to lymphoma or leukemia after being untreated for >10 years.ConclusionsEBV-infected lymphocyte profiling guided prolonged HCT-free control of CAEBV. CD4+ T-cell CAEBV requires a prompt rather than elective HCT to prevent progression and transformation.
academic.oup.com
September 25, 2026 at 2:30 AM
Companion paper: Differences in Hematopoietic Cell Transplantation Outcomes by #HIV status, California, 1991-2016 www.sciencedirect.com/science/arti... (subscription req for full text)
Differences in Hematopoietic Cell Transplantation Outcomes by HIV status, California, 1991-2016
Hematopoietic cell transplantation (HCT) can be curative for lymphoma, yet population-level HCT outcomes by HIV status are not well studied, contribut…
www.sciencedirect.com
September 24, 2026 at 4:36 PM
Trends and Predictors of Hematopoietic Cell Transplant Utilization for HIV-lymphoma in California, 1991-2016 www.sciencedirect.com/science/arti... (subscription req for full text) #HIV
Trends and Predictors of Hematopoietic Cell Transplant Utilization for HIV-lymphoma in California, 1991-2016
Hematopoietic cell transplant (HCT) is a potentially curative treatment for relapsed or refractory lymphoma, and population-level patterns of HCT util…
www.sciencedirect.com
September 24, 2026 at 4:23 PM
NOW AVAILABLE: 2014-2024 Non-Malignant Summary Slides. These slides detail the clinical practices, trends, and survival outcomes following HCT and cellular therapy, including gene therapy for non-malignant diseases. Learn more: cibmtr.org/CIBMTR/Resou...
September 24, 2026 at 3:40 PM
📱 A technology-enabled education program nearly tripled skinc ancer screening among HCT survivors, who face elevated long-term risk.

➡️ Outreach to survivors and PCPs could close gaps in cancer survivorship care

🔸Saro Armenian, DO, MPH | JNCCN

🔗 https://ow.ly/Ck4I50Zzxwn
September 24, 2026 at 1:00 PM
http://www.emediawire.com/releases/2005/6/emw249802.htm

Cowboys – Need Not Apply; Teaching the Right Stuff – for Hostile Conditions

HCT (Hostile Control Tactics, LLC) meets growing need for training PM…

http://localhost:10018/cowboys-need-not-apply-teaching-the-right-stuff-for-hostile-conditions/
Cowboys – Need Not Apply; Teaching the Right Stuff – for Hostile Conditions
http://www.emediawire.com/releases/2005/6/emw249802.htm Cowboys – Need Not Apply; Teaching the Right Stuff – for Hostile Conditions HCT (Hostile Control Tactics, LLC) meets growing need for training PMCs (Private Military Contractors) and security…
localhost
September 24, 2026 at 10:13 AM
CuspHanger has been getting a lot of attention lately! So I wanted to honour the paper triggering its development:

Palettes can now be generated in CIELuv, the space Wijffelaars et al. originally used.

meodai.github.io/cusphanger

(Adds HCT as well, mostly because I wanted to try it)
September 24, 2026 at 9:48 AM
🔎 Discover September's Top Picks from Bone Marrow Transplantation, the official journal of EBMT: https://www.ebmt.org/ebmt/news/top-picks-bone-marrow-transplantation-7

#HCT #CellTherapy #Research #hematology
September 24, 2026 at 9:00 AM
looking forward to diving into this "How I Treat" by @drchrishourigan.bsky.social et al on incorporation of MRD into allo-HCT decision-making for AML!

ashpublications.org/blood/articl...
September 23, 2026 at 5:43 PM
🌍 Today marks #WorldMarrowDonorDay. We recognise donors, registries, healthcare professionals and everyone involved in connecting patients with a suitable donor. Thank you for bringing hope to patients around the world. 🙏

Learn more: worldmarrowdonorday.org

#ThankYouDonor #WMDD #WMDD26 #HCT
September 22, 2026 at 12:21 PM
Post-perihelion Photometric and Spectroscopic Monitoring of the Interstellar Comet 3I/ATLAS. Goldy Ahuja et. al. https://arxiv.org/abs/2609.22596
September 22, 2026 at 8:26 AM
刷了差不多半小时受不了了召唤hct出来解闷结果马上就刷出来了,神医啊
September 21, 2026 at 6:05 PM